文献速递前列腺癌

177Lu-PSMA-617联合Idronoxil(NOX66)治疗终末期转移性去势抵抗性前列腺癌的I/II期试验(LuPIN)

Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN).
PubMed 文献 · Eur Urol Oncol · 2020-08-03

这项I/II期试验纳入32例经紫杉类化疗及阿比特龙和/或恩扎卢胺治疗后的进展性mCRPC患者,评估177Lu-PSMA-617联合Idronoxil栓剂的安全性及活性。常见不良事件为口干、乏力和贫血,NOX66相关肛门刺激发生率为28%;91%患者出现任何PSA反应,62.5%患者PSA下降>50%,中位PSA无进展生存期为6.1个月,中位总生存期为17.1个月。结论认为该联合方案在三级及以上治疗中安全可行。

要点

  • 177Lu-PSMA-617联合NOX66在经多线治疗的mCRPC中安全可行。
  • 91%患者出现任何PSA反应,62.5%患者PSA下降>50%。
  • 中位PSA无进展生存期6.1个月,中位总生存期17.1个月。

核心结论

  • NOX66联合LuPSMA-617是经三级及以上治疗的mCRPC患者安全且可行的治疗策略。

研究设计与样本

  • I期剂量递增联合II期剂量扩展研究,纳入32例经紫杉类化疗(91%接受多西他赛和卡巴他赛)及阿比特龙和/或恩扎卢胺治疗后的进展性mCRPC患者。
  • 患者接受最多6个周期LuPSMA-617(7.5 GBq),第1天给药,联合NOX66第1-10天递增剂量,6周为一周期;队列1(n=8)接受400 mg,队列2(n=24)接受800 mg。

主要发现

  • 97%(31/32)接受至少两剂,47%(15/32)完成六剂。
  • 常见不良事件包括口干、乏力和贫血;NOX66相关肛门刺激发生率为28%。
  • 91%(29/32)出现任何PSA反应(中位-74%;95%CI 76-97),62.5%(20/32)PSA下降>50%(95%CI 45-77)。
  • 中位PSA无进展生存期为6.1个月(95%CI 2.8-9.2),中位总生存期为17.1个月(95%CI 6.5-27.1)。

临床怎么用

  • 对于经多线治疗后的终末期mCRPC患者,可考虑177Lu-PSMA-617联合NOX66方案,但需注意口干、乏力、贫血及肛门刺激等不良事件。

局限性

  • 样本量较小(32例),为I/II期试验,需进一步研究评估NOX66增强LuPSMA-617抗肿瘤效应的潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trials of lutetium prostate specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC) have demonstrated good safety and efficacy, but combination strategies may improve outcomes. Idronoxil is a synthetic flavonoid derivative with radiosensitising properties. OBJECTIVE: To evaluate the safety and activity of 177Lu PSMA 617 (LuPSMA-617) in combination with idronoxil suppositories (NOX66) in patients with end-stage mCRPC. DESIGN, SETTING, AND PARTICIPANTS: Thirty-two men with progressive mCRPC previously treated with taxane-based chemotherapy (91% treated with both docetaxel and cabazitaxel) and abiraterone and/or enzalutamide were enrolled in this phase I dose escalation study with phase II dose expansion. INTERVENTION: Screening with 68Ga PSMA and 18F-fludeoxyglucose positron emission tomography (PET)/computed tomography (CT) was performed. Men received up to six cycles of LuPSMA-617 (7.5 GBq) on day 1, with escalating doses of NOX66 on days 1-10 of a 6-wk cycle. Cohort 1 (n = 8) received 400 mg and cohort 2 (n = 24) 800 mg of NOX66. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Adverse events (AEs), pain inventory scores, prostate-specific antigen (PSA) response, progression-free survival, and overall survival were evaluated. RESULTS AND LIMITATIONS: Fifty-six men were screened and 32 (57%) were enrolled with a screen failure rate of 21% for PET imaging criteria. Dosing was as follows: 97% (31/32) received two or more doses and 47% (15/32) completed six doses. Common AEs included xerostomia, fatigue, and anaemia. Anal irritation attributable to NOX66 occurred in 28%. PSA responses were as follows: 91% (29/32) had any PSA response (median -74%; 95% confidence interval [CI] 76-97) and 62.5% (20/32) had a PSA fall of >50% (95% CI 45-77). The median PSA progression-free survival was 6.1 mo (95% CI 2.8-9.2) and median overall survival was 17.1 mo (95% CI 6.5-27.1). CONCLUSIONS: NOX66 with LuPSMA-617 is a safe and feasible therapeutic strategy in men treated with third-line therapy and beyond for mCRPC. PATIENT SUMMARY: Addition of NOX66 to 177Lu prostate-specific membrane antigen 617 is safe, and further studies are needed to assess its potential to augment the anticancer effects of LuPSMA-617.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Crumbaker M, Pathmanandavel S, Yam AO, et al. Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN). Eur Urol Oncol. 2020. PMID: 32758400. doi:10.1016/j.euo.2020.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。